Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#2919 Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II Studies of Lu-Octreotate Peptide Receptor Radionuclide Therapy (LuTate PRRT) +/- Capecitabine, Temozolomide (CAPTEM) or CAPTEM Alone for Neuroendocrine Tumours (NETs

Introduction: Chemotherapy is often combined with PRTT to treat NETs of pancreatic or midgut origin (pNET/mNET) based on the principle of radiosensitization.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Pavlakis N

Authors: Pavlakis N, Ransom D, Wyld D, Sjoquist K, Asher R,

Keywords: Lutate, PRRT, chemotherapy, CAPTEM, NETs,

#1893 Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)

Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Hayes A, Hosking E, Thomas D, Sjoquist K, Chan D,

Keywords: prognostic, biomarker, PRRT, LuTate,